OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 151 filers reported holding OCULAR THERAPEUTIX INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $211,021 | -3.2% | 67,204 | +59.1% | 0.00% | – |
| Q2 2023 | $217,907 | -2.8% | 42,230 | -0.7% | 0.00% | – |
| Q1 2023 | $224,070 | -29.2% | 42,518 | -62.2% | 0.00% | -100.0% |
| Q4 2022 | $316,434 | +486.0% | 112,610 | +767.4% | 0.00% | – |
| Q3 2022 | $54,000 | -62.0% | 12,982 | -63.3% | 0.00% | – |
| Q2 2022 | $142,000 | +0.7% | 35,342 | +24.5% | 0.00% | – |
| Q1 2022 | $141,000 | -6.6% | 28,395 | +30.7% | 0.00% | – |
| Q4 2021 | $151,000 | -76.7% | 21,720 | -66.4% | 0.00% | -100.0% |
| Q3 2021 | $647,000 | -22.2% | 64,682 | +10.2% | 0.00% | 0.0% |
| Q2 2021 | $832,000 | -22.1% | 58,675 | -9.8% | 0.00% | -50.0% |
| Q1 2021 | $1,068,000 | +5.7% | 65,077 | +33.4% | 0.00% | 0.0% |
| Q4 2020 | $1,010,000 | +134.3% | 48,786 | -13.8% | 0.00% | +100.0% |
| Q3 2020 | $431,000 | -29.3% | 56,615 | -22.7% | 0.00% | 0.0% |
| Q2 2020 | $610,000 | +365.6% | 73,210 | +244.4% | 0.00% | – |
| Q3 2017 | $131,000 | – | 21,256 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |